179 related articles for article (PubMed ID: 35437837)
1. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.
Klein S; Gashaw I; Baumann S; Chang X; Hummel T; Thuß U; Friedrich C
Br J Clin Pharmacol; 2022 Oct; 88(10):4552-4564. PubMed ID: 35437837
[TBL] [Abstract][Full Text] [Related]
2. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
Francke K; Chattopadhyay N; Klein S; Rottmann A; Krickau D; van de Wetering J; Friedrich C
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):75-87. PubMed ID: 36469250
[TBL] [Abstract][Full Text] [Related]
4. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
[TBL] [Abstract][Full Text] [Related]
5. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
6. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
7. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.
Davenport AJ; Neagoe I; Bräuer N; Koch M; Rotgeri A; Nagel J; Laux-Biehlmann A; Machet F; Coelho AM; Boyce S; Carty N; Gemkow MJ; Hess SD; Zollner TM; Fischer OM
Sci Rep; 2021 Oct; 11(1):19877. PubMed ID: 34615939
[TBL] [Abstract][Full Text] [Related]
8. Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
Fuertig R; Goettel M; Herich L; Hoefler J; Wiebe ST; Sharma V
CNS Drugs; 2023 Dec; 37(12):1081-1097. PubMed ID: 38019355
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
10. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
11. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study.
Dicpinigaitis PV; Morice AH; Smith JA; Sher MR; Vaezi M; Guilleminault L; Niimi A; Gude K; Krahn U; Saarinen R; Pires PV; Wosnitza M; McGarvey L;
Lung; 2023 Jun; 201(3):255-266. PubMed ID: 37261531
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.
Jin C; Yi C; Chen K; Liang H
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388
[TBL] [Abstract][Full Text] [Related]
15. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Garceau D; Chauret N
Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects.
Wang S; Chen G; Merlo Pich E; Affinito J; Cwik M; Faessel H
Br J Clin Pharmacol; 2021 Nov; 87(11):4354-4365. PubMed ID: 33837574
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
18. Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Zhang M; Xu C; Ma L; Shamiyeh E; Yin J; von Moltke LL; Smith WB
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):315-21. PubMed ID: 27136912
[TBL] [Abstract][Full Text] [Related]
19. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study.
Wang H; Liu H; Liu M; Wang W; Zhu L; Huang H; Hu P; Jiang J
Eur J Pharm Sci; 2017 Mar; 100():87-93. PubMed ID: 28057550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
